Patents by Inventor Peter Van Hoogevest

Peter Van Hoogevest has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10603384
    Abstract: The invention relates to pharmaceutical compositions, particularly for intravenous administration, containing {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid in combination with at least one of the cyclodextrin excipients, lysine and arginine; the method for its production; and its use in methods of treatment of and/or as a prophylactic for illnesses, particularly its use as an antiviral, preferably against cytomegaloviruses.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: March 31, 2020
    Assignee: AICURIS GMBH & CO. KG
    Inventors: Kerstin Paulus, Wilfried Schwab, Dominique Grunder, Peter Van Hoogevest
  • Publication number: 20160299113
    Abstract: There are described solid compositions or examining drug solubility comprising bile salts and phospholipids, optionally containing buffer components suitable for preparation of intestinal media that simulate the composition of the intestinal fluids in fasted and fed states.
    Type: Application
    Filed: November 18, 2014
    Publication date: October 13, 2016
    Inventors: Steve Leigh, Mathew Louis Steven Leigh, Peter Van Hoogevest, Daniel Streich, Jacques Quinton
  • Publication number: 20150133461
    Abstract: The invention relates to pharmaceutical compositions, particularly for intravenous administration, containing {8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazoline-4-yl}acetic acid in combination with at least one of the cyclodextrin excipients, lysine and arginine; the method for its production; and its use in methods of treatment of and/or as a prophylactic for illnesses, particularly its use as an antiviral, preferably against cytomegaloviruses.
    Type: Application
    Filed: February 28, 2013
    Publication date: May 14, 2015
    Applicant: AICURIS GMBH & CO. KG
    Inventors: Kerstin Paulus, Wilfried Schwab, Dominique Grunder, Peter Van Hoogevest
  • Patent number: 9005597
    Abstract: The present invention is directed to a composition for treating vaginal dryness and lack of lubrication comprising: a poloxamer component; a phospholipid component; an optional oil component; and a non-aqueous carrier; wherein the composition is substantially anhydrous. In another aspect, the present invention is directed to a method of treating vaginal dryness comprising the step of administering to a patient suffering from vaginal dryness the above composition.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: April 14, 2015
    Assignee: Medlite A/S
    Inventors: Ketil Andre Hansen, Tore Fagerland, John Afseth, Matthew Leigh, Elsa Kung, Peter van Hoogevest
  • Publication number: 20150037397
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of formula (I) and a cyclodextrin or a liposome, to the process of preparing said compositions and their use for antitumor, antiviral, antiparasitic and antifungal treatment.
    Type: Application
    Filed: December 22, 2011
    Publication date: February 5, 2015
    Applicant: TRASLATIONAL CANCER DRUGS PHARMA, S.L.
    Inventors: Beatriz Palacios Izquierdo, Peter Van HoogeVest, Mathew L.S. Leigh
  • Patent number: 8889189
    Abstract: There are described solid compositions or examining drug solubility comprising bile salts and phospholipids, optionally containing buffer components suitable for preparation of intestinal media that simulate the composition of the intestinal fluids in fasted and fed states.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: November 18, 2014
    Assignee: Phares Pharmaceutical Research, N.V.
    Inventors: Steve Leigh, Mathew Louis Steven Leigh, Peter Van Hoogevest, Daniel Streich, Jacques Quinton
  • Patent number: 8753652
    Abstract: The present invention relates to a pharmaceutical composition to be parenterally administered, including submicronic ester particles of docosahexaenoic acid, dispersed in an aqueous phase using a mixture of at least two surfactants selected from among a) at least one polyoxyethylene fatty acid ester and b) at least one phospholipid derivative. The present invention also relates to the method for preparing said pharmaceutical composition.
    Type: Grant
    Filed: August 11, 2010
    Date of Patent: June 17, 2014
    Assignee: Pierre Fabre Medicament
    Inventors: Elie Leverd, Peter Van Hoogevest, Elsa Kung, Mathew Leigh
  • Patent number: 8632832
    Abstract: The present disclosure describes a method for the continuous dissolution of e.g. crystalline astaxanthin or canthaxanthin suspension in oil, by applying heat for a predetermined period using an in-line or optionally batch wise-process, followed by cooling the heated solution with an oil phase or heat exchanger. The resulting oil solution may be used as such or added directly to feed components which are turned into feed compositions by extrusion, compaction or granulation. Alternatively the oil solution is spray coated or directly loaded to extruded or compacted pellets and granulates. The disclosure avoids using formulated carotenoids prepared by known multi-step production methods requiring solvents, solvent removal, cooling and emulsification with an aqueous phase or precipitation and recovery steps.
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: January 21, 2014
    Assignee: Phares Pharmaceutical Research N.V.
    Inventors: Steve Leigh, Mathew Louis Steven Leigh, Peter Van Hoogevest
  • Patent number: 8287907
    Abstract: There are described solid compositions or examining drug solubility comprising bile salts and phospholipids, optionally containing buffer components suitable for preparation of intestinal media that simulate the composition of the intestinal fluids in fasted and fed states.
    Type: Grant
    Filed: November 10, 2006
    Date of Patent: October 16, 2012
    Assignee: Phares Pharmaceutical Research, N.V.
    Inventors: Steve Leigh, Matthew Louis Steven Leigh, Peter Van Hoogevest, Daniel Streich, Jacques Quinton
  • Publication number: 20120141563
    Abstract: The present invention relates to a pharmaceutical composition to be parenterally administered, including submicronic ester particles of docosahexaenoic acid, dispersed in an aqueous phase using a mixture of at least two surfactants selected from among a) at least one polyoxyethylene fatty acid ester and b) at least one phospholipid derivative. The present invention also relates to the method for preparing said pharmaceutical composition.
    Type: Application
    Filed: August 11, 2010
    Publication date: June 7, 2012
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Elie Leverd, Peter Van Hoogevest, Elsa Kung, Mathew Leigh
  • Publication number: 20110262381
    Abstract: The present invention is directed to a composition for treating vaginal dryness and lack of lubrication comprising: a poloxamer component; a phospholipid component; an optional oil component; and a non-aqueous carrier; wherein the composition is substantially anhydrous. In another aspect, the present invention is directed to a method of treating vaginal dryness comprising the step of administering to a patient suffering from vaginal dryness the above composition.
    Type: Application
    Filed: October 29, 2009
    Publication date: October 27, 2011
    Inventors: Ketil Andre Hansen, Tore Fagerland, John Afseth, Mathew Leigh, Elsa Kung, Peter Van Hoogevest
  • Publication number: 20110244028
    Abstract: The invention describes a method of preparing lipid compositions by associating pH sensitive compounds which maybe weak acids, bases or amphoteric compounds with at least one ionisable or pH sensitive group and low water solubility into preformed and standardised lipid particles by pH manipulation. Drug association is carried out in situ by changing the pH of the aqueous medium to pH 6-8 wherein the compound spontaneously partitions into the lipid particles. Drug association may also be carried out by exploiting pH changes in the GI tract. The lipophilic compound is solubilised by the lipid particles and may be used as such for in-vitro and pharmacokinetic assessments or processed for oral, parenteral or topical therapy.
    Type: Application
    Filed: September 28, 2009
    Publication date: October 6, 2011
    Inventors: Steve Leigh, Mathew Leuis Steven Leigh, Peter Van Hoogevest
  • Publication number: 20110124691
    Abstract: Pharmaceutical formulations comprising an epothilone in the form of an infusion concentrate or a lyophilised composition, and methods of administration of an epothilone in suitable form for parenteral administration.
    Type: Application
    Filed: February 4, 2011
    Publication date: May 26, 2011
    Inventor: Peter van Hoogevest
  • Patent number: 7563935
    Abstract: Mixtures of specific crystal forms of astaxanthin and the individual crystal forms designated crystal Form I and II and disclosed together with methods for preparing said crystal Forms. Methods for preparing nutritional dosage forms including the disclosed astaxanthin crystal forms for the life science industry are also disclosed.
    Type: Grant
    Filed: February 15, 2008
    Date of Patent: July 21, 2009
    Assignee: Phares Pharmaceutical Research N.V. et al.
    Inventors: Steve Leigh, Mathew Louis Steven Leigh, Peter Van Hoogevest
  • Publication number: 20090145248
    Abstract: There are described solid compositions or examining drug solubility comprising bile salts and phospholipids, optionally containing buffer components suitable for preparation of intestinal media that simulate the composition of the intestinal fluids in fasted and fed states.
    Type: Application
    Filed: November 10, 2006
    Publication date: June 11, 2009
    Applicant: PHARES PHARMACEUTICAL RESEARCH N.V.
    Inventors: Steve Leigh, Matthew Louis Steven Leigh, Peter Van Hoogevest, Daniel Streich, Jacques Quinton
  • Publication number: 20080311267
    Abstract: The present disclosure describes a method for the continuous dissolution of e.g. crystalline astaxanthin or canthaxanthin suspension in oil, by applying heat for a predetermined period using an in-line or optionally batch wise-process, followed by cooling the heated solution with an oil phase or heat exchanger. The resulting oil solution may be used as such or added directly to feed components which are turned into feed compositions by extrusion, compaction or granulation. Alternatively the oil solution is spray coated or directly loaded to extruded or compacted pellets and granulates. The disclosure avoids using formulated carotenoids prepared by known multi-step production methods requiring solvents, solvent removal, cooling and emulsification with an aqueous phase or precipitation and recovery steps.
    Type: Application
    Filed: November 21, 2007
    Publication date: December 18, 2008
    Applicant: PHARES PHARMACEUTICAL RESEARCH
    Inventors: Steve Leigh, Mathew Louis Steven Leigh, Peter Van Hoogevest
  • Publication number: 20080234521
    Abstract: Mixtures of specific crystal forms of astaxanthin and the individual crystal forms designated crystal Form I and II and disclosed together with methods for preparing said crystal Forms. Methods for preparing nutritional dosage forms including the disclosed astaxanthin crystal forms for the life science industry are also disclosed.
    Type: Application
    Filed: February 15, 2008
    Publication date: September 25, 2008
    Applicant: PHARES PHARMACEUTICAL RESEARCH N. V.
    Inventors: Steve LEIGH, Mathew Louis Steven Leigh, Peter Van Hoogevest
  • Publication number: 20080221065
    Abstract: Pharmaceutical formulations comprising an epothilone in the form of an infusion concentrate or a lyophilised composition, and methods of administration of an epothilone in suitable form for parenteral administration.
    Type: Application
    Filed: May 20, 2008
    Publication date: September 11, 2008
    Applicant: NOVARTIS AG
    Inventor: Peter van Hoogevest
  • Publication number: 20080131499
    Abstract: Compositions for forming molecular associates with lipophilic compounds and an improved method of loading lipophilic biologically active compounds into previously formed, aqueous suspensions of lipid particles. A preferred embodiment for injection purposes comprise lipid particles having sizes below 1000 nm in diameter, in a vial or other suitable container are described. The method involves mixing a lipophilic compound either in solution or as an amorphous, preferably lyophilised powder in a first container with an aqueous suspension of lipid particles contained in a second container to form molecular associates. Only minimum agitation is required. The entire procedure may be carried out instantly in situ, in sealed sterile units just prior to use in the hospital ward or by the bedside.
    Type: Application
    Filed: January 2, 2008
    Publication date: June 5, 2008
    Applicant: PHARES PHARMACEUTICAL RESEARCH N.V.
    Inventors: Steven Leigh, Mathew Louis Steven Leigh, Peter Van Hoogevest, Henricus Tiemessen
  • Publication number: 20060286169
    Abstract: There is described dry compositions comprising lipophilic compounds associated with low viscosity grades of water insoluble polymer and optionally hydrophilic agent/s associated either as monomolecular or amorphous complexes. There is also described a method of preparing said lipophilic polymer complexes from a solution or homogeneous dispersion employing either water miscible or immiscible organic solvents. The lipophilic polymer complex is precipitated from the solution comprising a water miscible solvent by dilution with water, separating out the precipitated complex, washing, drying and conversion to oral and topical dosage forms. The lipophilic polymer complex may also be prepared by solvent removal involving spray drying or vacuum drying under elevated temperatures using either water miscible or water immiscible solvents. The compositions are characterised by improved dissolution and solubility of the associated compound in aqueous medium.
    Type: Application
    Filed: February 13, 2004
    Publication date: December 21, 2006
    Applicant: Phares Pharmaceutical Research N.V.
    Inventors: Mathew Leigh, Peter Van Hoogevest, Jacques Quinton, Steve Leigh